Literature DB >> 15570035

Docosahexaenoic acid attenuates mycotoxin-induced immunoglobulin a nephropathy, interleukin-6 transcription, and mitogen-activated protein kinase phosphorylation in mice.

Qunshan Jia1, Hui-Ren Zhou, Maurice Bennink, James J Pestka.   

Abstract

The purpose of this investigation was to evaluate the dose-dependent effects of docosahexaenoic acid (DHA) on deoxynivalenol (DON)-induced IgA nephropathy in mice and their relation to proinflammatory gene expression and mitogen-activated protein kinase (MAPK) activation. Consumption of a modified AIN-93G diet containing 1, 5, and 30 g/kg DHA resulted in dose-dependent increases of DHA in liver phospholipids with concomitant decreases in arachidonic acid compared with control diets. DHA dose dependently inhibited increases in serum IgA and IgA immune complexes (IC) as well as IgA deposition in the kidney in DON-fed mice; the 30 g/kg DHA diet had the earliest detectable effects and maximal efficacy. Both splenic interleukin-6 (IL-6) mRNA and heterogeneous nuclear RNA (hnRNA), an indicator of IL-6 transcription, were significantly reduced in DON-fed mice that consumed 5 and 30 g/kg DHA; a similar reduction was observed for cyclooxygenase (COX-2) mRNA. In a subsequent study, acute DON exposure (25 mg/kg body weight) induced splenic IL-6 mRNA and hnRNA as well as COX-2 mRNA in mice fed the control diet, whereas induction of both RNA species was significantly inhibited in mice fed 30 g/kg DHA. These latter inhibitory effects corresponded to a reduction in DON-induced phosphorylation of p38, extracellular-signal related kinase 1/2, and c-Jun N-terminal kinase 1/2 MAPKs in the spleen. Taken together, the results indicate that DHA dose-dependently inhibited DON-induced IgA dysregulation and nephropathy, and that impairment of MAPK activation and expression of COX-2 and IL-6 are potential critical upstream mechanisms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570035     DOI: 10.1093/jn/134.12.3343

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  8 in total

1.  NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury.

Authors:  Guangbi Li; Zhida Chen; Owais M Bhat; Qinghua Zhang; Justine M Abais-Battad; Sabena M Conley; Joseph K Ritter; Pin-Lan Li
Journal:  J Lipid Res       Date:  2017-04-12       Impact factor: 5.922

Review 2.  n-3 polyunsaturated fatty acids and autoimmune-mediated glomerulonephritis.

Authors:  James J Pestka
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2010-03-01       Impact factor: 4.006

3.  Fish oil supplementation inhibits NNK-induced lung carcinogenesis in the A/J mouse.

Authors:  Heather Mernitz; Fuzhi Lian; Donald E Smith; Simin Nikbin Meydani; Xiang-Dong Wang
Journal:  Nutr Cancer       Date:  2009       Impact factor: 2.900

4.  Mechanisms for suppression of interleukin-6 expression in peritoneal macrophages from docosahexaenoic acid-fed mice.

Authors:  Yuhui Shi; James J Pestka
Journal:  J Nutr Biochem       Date:  2008-07-07       Impact factor: 6.048

Review 5.  Deoxynivalenol-induced proinflammatory gene expression: mechanisms and pathological sequelae.

Authors:  James J Pestka
Journal:  Toxins (Basel)       Date:  2010-06-01       Impact factor: 4.546

6.  How dietary arachidonic- and docosahexaenoic- acid rich oils differentially affect the murine hepatic transcriptome.

Authors:  Alvin Berger; Matthew A Roberts; Bruce Hoff
Journal:  Lipids Health Dis       Date:  2006-04-20       Impact factor: 3.876

7.  The Renoprotective Effects of Docosahexaenoic Acid as an Add-on Therapy in Patients Receiving Eicosapentaenoic Acid as Treatment for IgA Nephropathy: A Pilot Uncontrolled Trial.

Authors:  Takahito Moriyama; Saeko Kumon; Takahiro Kamiyama; Kazunori Karasawa; Keiko Uchida; Kosaku Nitta
Journal:  Intern Med       Date:  2017-11-01       Impact factor: 1.271

8.  Influence of Polyunsaturated Fatty Acid Intake on Kidney Functions of Rats with Chronic Renal Failure.

Authors:  Hiroki Muramatsu; Naoe Akimoto; Michio Hashimoto; Kenji Sugibayashi; Masanori Katakura
Journal:  Mar Drugs       Date:  2021-12-03       Impact factor: 5.118

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.